Omnicell (OMCL) Releases Earnings Results, Beats Expectations By $0.09 EPS

Omnicell (OMCL) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $0.35 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.09. Analysts had a consensus of $0.26. The company posted revenue of $171.00 million in the period, compared to analysts expectations of $167.17 million. The company’s revenue was up 47.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 EPS.

Many Wall Street Analysts have commented on Omnicell. Shares were Reiterated by Topeka Capital Markets on Mar 21, 2016 to “Buy” and Lowered the Price Target to $ 37 from a previous price target of $38 .

Omnicell opened for trading at $30.06 and hit $30.68 on the upside on Wednesday, eventually ending the session at $30.66, with a gain of 1.42% or 0.43 points. The heightened volatility saw the trading volume jump to 1,61,079 shares. Company has a market cap of $1,099 M.

In a different news, on Apr 26, 2016, Robin Gene Seim (EVP, Global A & M Adherence) sold 767 shares at $30.00 per share price. According to the SEC, on Apr 26, 2016, Jorge R. Taborga (Executive VP. Engineering) sold 23,827 shares at $30.00 per share price. On Feb 22, 2016, Dan S Johnston (EVP-Chief Legal & Admin Off) sold 8,850 shares at $27.42 per share price, according to the Form-4 filing with the securities and exchange commission.

Omnicell Inc. (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company has two operating segments: Automation and Analytics and Medication Adherence. The Automation and Analytics segment is organized around the design manufacturing selling and servicing of medication and supply dispensing systems pharmacy inventory management systems and related software. The Medication Adherence segment primarily includes the manufacturing and selling of consumable medication blister cards packaging equipment and ancillary products and services. The Company’s products include OmniRx SinglePointe AnywhereRN OptiFlex MS OptiFlex CL AccuFlex Autobond AutoGen and SureSeal among others.


Leave a Reply

Omnicell - Is it time to Sell?

Top Brokerage Firms are advising their investors on Omnicell. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.